A phase 2, single arm study of BSI-201 in patients with BRCA-1 or BRCA-2 associated advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Phase of Trial: Phase II
Latest Information Update: 01 Feb 2016
At a glance
- Drugs Iniparib (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Sponsors Sanofi
- 10 Jun 2017 Biomarkers information updated
- 01 Aug 2012 Actual end date changed from Aug 2011 to Jun 2011, as reported by ClinicalTrials.gov.
- 04 Jun 2012 Actual patient number chnaged from 45 to 12 as reported by ClinicalTrials.gov record.